Sage Journals: Discover world-class research

Abstract

This paper examines pharmaceutical cost control approaches associated with managed care, including drug formularies, drug co-payments, therapeutic drug interchanges, drug utilisation reviews and step therapies. The need for pharmacoeconomic analysis is stressed. Finally, the impact of governmental and market approaches to pharmaceutical cost control are discussed.

Keywords

drug utilisation reviews formulary global managed care international pharmaceutical costs pharmacoeconomics therapeutic drug interchanges

Get full access to this article

View all access options for this article.

References

Douthat

Poe

(2005) ‘The graying globe’, Atlantic, 296(1), 47.

Drummond

Jonsson

(2003) ‘Moving beyond the drug budget silo mentality in Europe’, Value in Health, 6(4), S74–S77.

Drummond

Jonsson

(2005) ‘Drug fix’, Business Review Weekly, 27(22), 31.

Moynihan

(2004) ‘Drug spending in North America rose by 11% in 2003’, British Medical Journal 328(7442), 727.

CIA-US (2005) The World Factbook: United States. Available at: http://www.cia.gov/cia/publications/factbook/geos/us.html#People (Accessed 6 July 2005).

CIA-US (2005) Demographic Statistics, 1 April. Available at: http://www.statcan.ca/Daily/English/050629/d050629d.htm (Accessed 6 July 2005).

CIA-World (2005) The World Factbook: World. Available at: http://www.cia.gov/cia/publications/factbook/geos/xx.html#People (Accessed 6 July 2005).

Javalgi

R.G.

Wright

R.F.

(2003) ‘An international market entry model for pharmaceutical companies: A conceptual framework for strategic decisions’, International Journal of Medical Marketing, 3(4), 274–286.

Rugman

A.M.

Brain

(2004) ‘Regional strategies of multinational pharmaceutical firms’, Management International Review, 44, 7–25.

10.

US Market Share (2004) US Market Share Continues to Expand. Available at: http://www.ims-global.com/insight/news_story/0401/news_story_040112.htm (Accessed 7 June 2005).

11.

Richardson

Luchsinger

(2004) ‘International pharmaceuticals industry: The new marketing paradigm in the United States and unresolved issues of public policy’, Journal of the American Academy of Business, 5(1/2), 21–25.

12.

IMS Health Pharmaceutical World Review (2003) Available at: www.ims-global.com (Accessed May 2005).

13.

Weidenbaum

(1993) ‘Restraining medicine prices: Controls vs. competition’, Policy Study No. 116, Center for the Study of American Business, Washington University, St Louis, MO. Available at: www.ncpa.org/ea/eaja93/eaja93m.html (Accessed May 2005).

14.

PhRMA (2005) Research and Development Overview. Available at: www.phrma.org/issues/researchdev/(Accessed May 2005).

15.

Pharmaprojects (2003) Annual Review. PJB Publications, London.

16.

PhRMA (2005) 146 New Medicines now in Pipeline to Fight Heart Disease and Stroke. Available at: www.phrma.org/mediaroom/press/releases/28.02.2005.1131.cfm (Accessed May 2005).

17.

PhRMA (2005) 399 New Medicines in Development to Treat Cancer. Available at: www.phrma.org/mediaroom/press/releases/17.05.2005.1174.cfm (Accessed May 2005).

18.

PhRMA (2004) Pharmaceutical Marketing and Promotion. Available at: www.phrma.org/publications/policy//2004-11-10.1095.pdf (Accessed 6 July 2005).

19.

Matthews

Jr. (2001) ‘Who's afraid of pharmaceutical advertising? A response to a changing health care system’, IPI Policy Report 155. Available at:www.ipi.org/ipi/IPIPublications.nsf/PublicationLookupFullText/F4F61FB6BB576D4086256A4F00229C21 (Accessed May 2005).

20.

PhRMA (2004) op. cit..

21.

Findlay

(2001) ‘Direct-to-consumer promotion of prescription drugs: Economic implications for patients, payers and providers’, Pharmacoeconomics 19(2), 109–119.

22.

Anonymous (1999) ‘Direct-to-consumer media: Highly critical articles on drug pricing, advertising’, Medical Marketing & Media, 34(1), 24.

23.

McInturff

(2001) ‘While critics may fret, public likes DTC ads’, Advertising Age, 72(13), 24.

24.

Teinowitz

(2001) ‘DTC regulation by FDA debated’, Advertising Age, 72 (31), 6.

25.

Siegel

Lyn

(2000) ‘DTC advertising: Bane or blessing?’, Pharmaceutical Executive, 20(10), 140–152.

26.

Dubois

R.W.

Chawla

A.J.

Nesluan

C.A.

Smith

M.W.

Wade

(2000) ‘Explaining drug spending trends: Does perception match reality?’, Health Affairs, 19(2), 231–239.

27.

Findlay

(2002) ‘Do ads really drive pharmaceutical sales?’, Marketing Health Services, 22(1), 20–25.

28.

US Food and Drug Administration (2003) ‘Frequently asked questions on the Patent Term Restoration Program’, Center for Drug Evaluation and Research. Available at: www.fda.gov/cder/about/smallbiz/patent_term.htm (Accessed 6 July 2005).

29.

DiMasi

J.A.

Hansen

R.W.

Grabowski

H.G.

(2003) ‘The price of innovation: New estimates of drug development costs’, Journal of Health Economics, 22(2), 151–185.

30.

Bartlett

(2000) U.S. Spending on Prescription Drugs. Available at: www.ncpa.org/pi/health/pd090500a.html(Accessed May 2005).

31.

Koretz

(2000) ‘Why those drug costs are up’, Business Week, 6 November, 36.

32.

Burton

T.M.

(1998) ‘Hard to swallow: America's soaring drug costs’, Wall Street Journal, 16 November, A1.

33.

Smith

M.C.

Kolassa

E.M. ‘Mick’

Perkins

Siecker

(2002) Pharmaceutical Marketing: Principles, Environment, and Practice. Pharmaceutical Products Press, New York, 19.

34.

Burton (1998) op. cit..

35.

Fairman

(2001) Fact Sheet: Understanding the High-Cost Patient, Available at: www.ncpa.org/pi/health/pd062601d.html (Accessed May 2005).

36.

Kongstvedt

P.R.

(2002) ‘Network management and reimbursement’, in Knight

(ed.) Managed Care: What it is and How it Works, 2nd edn. Aspen Publishers, Inc., Gaithersburg, MD, 77–129.

37.

Navarro

R.P.

(2001) ‘Prescription drug benefits in managed care’, in Kongstvedt

P.R.

(ed.) Essentials of Managed Health Care, 4th edn. Aspen Publishers, Inc., Gaithersburg, MD, 293–328.

38.

Tamblyn

Abrahamowicz

Brailovsky

Grand'Maison

Lescop

Norcini

Girard

Haggerty

(2001) ‘Adverse events associated with prescription drug cost-sharing among poor and elderly persons’, Journal of the American Medical Association, 285(4), 421–429.

39.

Navarro (2001) op. cit..

40.

Christine-Herman

Emons

George

(2004) ‘Effects of generic-only drug coverage in a medicare HMO’, Health Affairs — Web Exclusive, 23(Supplement 2), W4-455–W4-468.

41.

Kamal-Bahl

Briescher

(2004) ‘How doincentive-based formularies influence drug selection and spending for hypertension?’, Health Affairs, 23(1), 227–236.

42.

Navarro (2001) op. cit..

43.

PhRMA (2004) op. cit..

44.

Greene

(2005) ‘A prescription for change: How the medicare act revises Hatch-Waxman to speed entry of generic drugs’, Journal of Corporation Law, 30(2), 309–355.

45.

Richardson Luchsinger (2004) op. cit..

46.

Parmenter

E.M.

(2004) ‘Health care benefit crisis: Cost drivers and strategic solutions’, Journal of Financial Service Professionals, 58(4), 63–78.

47.

Burton (1998) op. cit..

48.

Danzon

P.M.

Furukawa

M.F.

(2003) ‘Prices and availability of pharmaceuticals: Evidence from nine countries’, Health Affairs — Web Exclusives, July-December, W3-521–W3-536.

49.

Safran

D.G.

Neuman

Schoen

Kitchman

M.S.

Wilson

I.B.

Cooper

Chang

Rogers

W.H.

(2005) ‘Prescription drug coverage and seniors: Findings from a 2003 survey (4/19/05)’, Health Affairs — Web Exclusive. Available at: http:content.healthaffairs.org/cgi/content/abstract/hlthaff.w5.152 (Accessed 6 July 2005).

50.

Quirk

Maidwell

(2004) ‘The global cardiovascular drug market’, International Journal of Medical Marketing, 4(2), 96–101.

51.

White

T.J.

(2001) ‘Making pharmacoeconomics in formulary development a reality’, Managed Care, 10(2). Available at: www.managedcaremag.com/archives/0102/0102.formulary.html (Accessed May 2005).

52.

Baldwin

(2001) ‘Pharmacy benefit design trends’. Available at: www.pharmscope.com/news (Accessed November 2001).

53.

Navarro (2001) op. cit..

54.

White (2001) op. cit..

55.

White (2001) op. cit..

56.

Fairman (2001) op. cit..

57.

White (2001) op. cit..

58.

White (2001) op. cit..

59.

Ess

S.M.

Schneeweiss

Szucs

T.D.

(2003) ‘European healthcare policies for controlling drug expenditure’, Pharmacoeconomics, 21(2), 89–103.

60.

Drummond

(2004) ‘Economic evaluation in health care: Is it really useful or are we just kidding ourselves?’, The Australian Economic Review, 37(1), 3–11.

61.

McCain

(2001) System Helps P&T Committees Get Pharmacoeconomic Data They Need. Available at: www.managedcaremag.com/archives/0104/0104.amcp.htm (Accessed May 2005).

62.

Neumann

P.J.

(2004) ‘Evidence-based and value-based formulary guidelines’, Health Affairs, 23(1), 124–132.

63.

Milligan

(2003) ‘House passes bill to allow’ Americans to buy imported prescription drugs’, Knight Ridder Tribune Business News, 25 July, 1.

64.

Dalzell

M.D.

(2000) ‘Prescription drug reimportation: Panacea or problem?’, Managed Care, 9(12). Available at: www.managedcaremag.com/archives/0012/0012.reimport.html (Accessed May 2005).

65.

Ibid..

66.

Dorsey

(2001) ‘Progress slows on pharmaceutical reimportation amendment’, Des Moines Business Record, 22 October, 26.

67.

PhRMA (2004) op. cit..

68.

Koretz (2000) op. cit..

69.

Bartlett (2000) op. cit..

70.

Bartlett (2000) op. cit..

Global Pharmaceutical Costs: Evaluating the American Approach

Abstract

Keywords

Get full access to this article

References